Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases
Details : Under the terms of the agreement, Innovent will be responsible for the manufacture of the three programs through a Phase 2 study and, if Innovent exercises its option, research, development, and commercialization of each program in Greater China.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement